Clinical Trial

Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 10, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn if the SARS-CoV-2 subunit mucosal vaccine with the recombinant flagellin protein adjuvant works to Prevent COVID-19 infection. It will also learn about the Safety and immunogenicity of the vaccine.
Trial Details
NCT Number NCT06768697
Lead Sponsor Shanghai Public Health Clinical Center
Conditions COVID - 19
Enrollment 60 participants
Start Date 2024-12-30
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-10